SCHEMBL10162259

SCHEMBL10162259

CC(=O)C12CCC(CNC(=O)c3cc(C(=O)NCc4cccc(OC(F)F)c4)nc4ncnn34)(CC1)CC2

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 2/20 0.41
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KCNA5 P22460 1/20 0.38
KCNH2 Q12809 1/20 0.38
KCNB1 Q14721 1/20 0.38
ROCK2 O75116 3/20 0.36
ROCK1 Q13464 2/20 0.36
CLK1 P49759 1/20 0.36
MMP13 P45452 2/20 0.36
EGLN2 Q96KS0 1/20 0.35
KIT P10721 2/20 0.34
FPR3 P25089 1/20 0.34
FPR2 P25090 1/20 0.34
KLKB1 P03952 1/20 0.34
HPGD P15428 1/20 0.34
MBOAT4 Q96T53 1/20 0.34
GLS O94925 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162261 0.92 GLS (0.43) LMNAMAPK1SMN1; SMN2KCNB1ROCK2
SCHEMBL10162190 0.89 KCNA5 (0.39) KCNA5KCNH2KCNB1ROCK2ROCK1
SCHEMBL10162267 0.88 LMNA (0.39) PDE2ALMNASMN1; SMN2MMP13
SCHEMBL10162260 0.88 MBOAT4 (0.36) PDE2ALMNAMAPK1SMN1; SMN2MMP13
SCHEMBL10162223 0.87 MMP13 (0.41) KCNA5KCNH2KCNB1ROCK2ROCK1
SCHEMBL10162257 0.86 HRH4 (0.46) MMP13
SCHEMBL10162242 0.84 MMP13 (0.39) PDE2AMMP13
SCHEMBL10162262 0.84 SMN1; SMN2 (0.38) LMNAMAPK1SMN1; SMN2MMP13
SCHEMBL10162270 0.83 ALDH1A1 (0.33) LMNAMAPK1SMN1; SMN2MMP13HPGD
SCHEMBL10162240 0.83 MMP13 (0.48) PDE2AMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 PDE2A 1534/4885LMNA 2387/4885MAPK1 2860/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 PDE2A 1534/4885LMNA 2387/4885MAPK1 2860/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 PDE2A 1534/4885LMNA 2387/4885MAPK1 2860/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 PDE2A 1534/4885LMNA 2387/4885MAPK1 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.